Shopping Cart 0
Cart Subtotal
USD 0

Mumps - Pipeline Review, H1 2019

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Mumps-Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Mumps-Pipeline Review, H1 2019, provides an overview of the Mumps (Infectious Disease) pipeline landscape.

Mumps is a contagious disease that leads to painful swelling of the salivary glands. The mumps are caused by a virus. The virus is spread from person-to-person by respiratory droplets (for example, when you sneeze) or by direct contact with items that have been contaminated with infected saliva. Symptoms include fever, face pain, headache, sore throat, swelling of the temples or jaw and swelling of the parotid glands. Treatment includes pain relievers (to get relief for symptoms).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Mumps-Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Mumps (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Mumps (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Mumps and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and IND/CTA Filed stages are 2, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Mumps (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Mumps (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Mumps (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Mumps (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Mumps (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Mumps (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Mumps (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Mumps (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Mumps-Overview

Mumps-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Mumps-Therapeutics Assessment

Assessment by Route of Administration

Assessment by Molecule Type

Mumps-Companies Involved in Therapeutics Development

Cadila Healthcare Ltd

GlaxoSmithKline Plc

Sinovac Biotech Ltd

Mumps-Drug Profiles

(measles + mumps + rubella + varicella) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(measles + mumps + rubella) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(measles [strain Edmonston-Zagreb] + mumps [strain Hosino] + rubella [strain RA 27/3]) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(mumps + measles + rubella) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mumps vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mumps vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VN-0102-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Mumps-Dormant Projects

Mumps-Product Development Milestones

Featured News & Press Releases

Aug 03, 2018: Microgen a Russian developer releases vaccine for three diseases

Jun 13, 2012: UGA researcher developing new vaccine to fight resurging mumps virus

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Mumps, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019


List Of Table

List of Tables

Number of Products under Development for Mumps, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Mumps-Pipeline by Cadila Healthcare Ltd, H1 2019

Mumps-Pipeline by GlaxoSmithKline Plc, H1 2019

Mumps-Pipeline by Sinovac Biotech Ltd, H1 2019

Mumps-Dormant Projects, H1 2019

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Mumps Therapeutic Products under Development, Key Players in Mumps Therapeutics, Mumps Pipeline Overview, Mumps Pipeline, Mumps Pipeline Assessment


Companies

Cadila Healthcare Ltd

GlaxoSmithKline Plc

Sinovac Biotech Ltd

Mumps-Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Mumps-Pipeline Review, H1 2019, provides an overview of the Mumps (Infectious Disease) pipeline landscape.

Mumps is a contagious disease that leads to painful swelling of the salivary glands. The mumps are caused by a virus. The virus is spread from person-to-person by respiratory droplets (for example, when you sneeze) or by direct contact with items that have been contaminated with infected saliva. Symptoms include fever, face pain, headache, sore throat, swelling of the temples or jaw and swelling of the parotid glands. Treatment includes pain relievers (to get relief for symptoms).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Mumps-Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Mumps (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Mumps (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Mumps and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and IND/CTA Filed stages are 2, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Mumps (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Mumps (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Mumps (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Mumps (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Mumps (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Mumps (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Mumps (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Mumps (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Mumps-Overview

Mumps-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Mumps-Therapeutics Assessment

Assessment by Route of Administration

Assessment by Molecule Type

Mumps-Companies Involved in Therapeutics Development

Cadila Healthcare Ltd

GlaxoSmithKline Plc

Sinovac Biotech Ltd

Mumps-Drug Profiles

(measles + mumps + rubella + varicella) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(measles + mumps + rubella) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(measles [strain Edmonston-Zagreb] + mumps [strain Hosino] + rubella [strain RA 27/3]) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(mumps + measles + rubella) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mumps vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mumps vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VN-0102-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Mumps-Dormant Projects

Mumps-Product Development Milestones

Featured News & Press Releases

Aug 03, 2018: Microgen a Russian developer releases vaccine for three diseases

Jun 13, 2012: UGA researcher developing new vaccine to fight resurging mumps virus

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Mumps, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019


List Of Table

List of Tables

Number of Products under Development for Mumps, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Mumps-Pipeline by Cadila Healthcare Ltd, H1 2019

Mumps-Pipeline by GlaxoSmithKline Plc, H1 2019

Mumps-Pipeline by Sinovac Biotech Ltd, H1 2019

Mumps-Dormant Projects, H1 2019

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Mumps Therapeutic Products under Development, Key Players in Mumps Therapeutics, Mumps Pipeline Overview, Mumps Pipeline, Mumps Pipeline Assessment


Companies

Cadila Healthcare Ltd

GlaxoSmithKline Plc

Sinovac Biotech Ltd